Summary. Glucagon-like peptide-1 does not have specific, high-affinity receptors on rat liver membranes, does not displace glucagon from glucagon receptors on these membranes and does not stimulate the production of cyclic AMP by isolated rat hepatocytes. In the presence of glucagon, high concentrations of glucagon-like peptide-I do not significantly alter the production of cyclic AMR Thus, glucagon-like peptide-t appears unlikely to have a direct action on hepatic carbohydrate metabolism.
gon-like peptide sequences present in the C-terminal region of the deduced sequence of mammalian pre-proglucagon [1] . Its amino-acid sequence, completely conserved between hamster [1] , man [2] , ox [3] and rat [4] , presents a homology of 14 out of the 29 residues comparable with glucagon. It is present in extracts of human pancreas, although larger molecular forms predominate, and in glucagon-producing pancreatic tumours [5] . We have recently shown that GLP-1 does not have a glucagon-like effect on plasma glucose in cortisone-wetreated rabbits [6] , whilst others have demonstrated that GLP-1-(1-36)-peptide amide and human GLP-2 activate rat hypothalamic and pituitary adenylate cyclase [7] . In order to investigate further a possible role of GLP-1 in glucose metabolism, we have looked for evidence of specific, high-affinity GLP-1 receptors on rat liver membranes. We have also investigated whether GLP-1 was capable of stimulating cyclic AMP production in isolated rat hepatocytes. As the GLP-1 sequence ends with a glycine residue as a possible donor for Cterminal amidation [8] , both synthetic GLP-l-(1-37) and synthetic GLP-l-(a-36)-peptide amide were studied.
Materials and methods
Synthetic GLP-1-(1-36)-peptide amide was purchased from Peninsula Laboratories Inc., Behnont, CA, USA, and synthetic GLP-l-(1-37) from Bachem, Torrance, CA, USA. 125I-GLP-l-(1-37) was prepared by iodination with carrier-free Na12SI (IMS.30, Amersham International, Amersham, UK) using the chloramine-T method [9] . The iodihated peptide was separated from both unreacted iodine and unlabelled peptide by reverse-phase high pressure liquid chromatography on a Techsil 5 Ixm particle size octadecylsilylsilica column eluted with acetonitrile: water: trifluoroacetic acid 450:550:1 by volume. The labelled GLP-I-(1 37) showed a specific activity of 26 Bq/fmol.
The preparation of mono-12SI-glucagon, partially purified rat liver membranes and isolated rat hepatocytes, as well as the measurement of peptide binding to liver membranes and the production of cyclic AMP by rat hepatocytes, were carried out as described previously [10] .
For the measurement of peptide binding to liver membranes, the membranes (4150-4850 ~tg protein per ml) were incubated in Krebs Ringer phosphate buffer [10] , pH 7.5, containing 10 g/1 bovine serum albumin (BSA) with different concentrations of unlabelled glucagon, GLP-l-(1-37) or GLP-l-(1-36)-peptide amide and a constant concentration of mono-125I-glucagon (0.188 pmol/ml) or 12SI-GLP-l-(1-37) (0.85 pmol/ml) for 4 h at 10 ~ These conditions have been shown to give optimal specific l z5i.glucagon binding [10] . At the end of the incubation period, the samples (total volume 250 gl) were diluted out rapidly with I ml of ice-chilled buffer and immediately filtered on Oxoid filters (0.45 p~m pore-size) soaked in Krebs Ringer phosphate buffer containing 100 g/l BSA for at least I h before use. Non-specific adsorption of 125I-glucagon to the membranes was determined in the presence of 1 x 10-6mol/l unlabeUed glucagon.
The isolated hepatocytes were prepared from 48-h-fasted male Wistar rats by collagenase perfusion [10] . The cells (7.5 x 106/ml) were incubated at 37 ~ for 2.5 min with Krebs Ringer bicarbonate [10] , pH 7.4, containing 10retool/1 alanine, 2mmol/1 theophylline and 40g/l BSA. GLP-l-(l-37), GLP-1-(1-36)-peptide amide or glucagon were added at different concentrations in a total volume of 500 gl. At the end of the incubation period, the cell suspensions were treated twice with 0.5 ml of 100 g/l trichloroacetic acid, and the combined supernatants were washed with ether saturated with water.
Cyclic AMP was assayed by radioimmunoassay (Rianen cAMP [125I 1 RIA Kit, New England Nuclear Chemicals, Dreieich, FRG).
Results
Under the conditions of incubation and separation, non-specific binding of 12SI-glucagon was less than 2% of the total added. While unlabelled glucagon caused 50% displacement of 125I-glucagon (ED50) from its specific receptors at a concentration of 3 • 10 -9 mol/1, neither GLP-l-(I-37) nor GLP-1-(l-36)-peptide amide at concentrations up to 10 -6 mol/1 displaced a2SI-glucagon (Fig. 1, upper panel) . When the liver membranes were incubated in the presence of 125I-GLP-l-(1-37) at a concentration of 0.85 • 10-9mol/1, there was no displaceable binding of peptide to the membranes. Non-specific binding (in the presence of 2.4 • 10 -7 mol/l unlabelled peptide) was 3.2% of the total tracer added. specific binding of 125I-glucagon label. However, the results obtained are consistent with its lack of effect on plasma glucose concentrations at high doses in vivo [6] . Furthermore, the pancreas only produces small amounts of free GLP-1 [5] . All these data suggest that, despite its structural similarity with glucagon, the highly conserved GLP-1 must have a different biological role which would not include a direct action on hepatic carbohydrate metabolism. An intra-pancreatic or enteroinsular role for GLP-1 has been postulated on the basis of its glucose dependent insulinotropic action on isolated rat islets [11] . However, receptors for GLP- 1 have not yet been identified in endocrine pancreatic tissue. The evolutionary constraint that has conserved the structure of GLP-1 as completely as that of glucagon must arise from a physiological action that remains to be discovered.
